

## Elevated Phosphate Activates N-ras and Promotes Cell Transformation and Skin Tumorigenesis

Corinne E. Camalier<sup>1,3</sup>, Matthew R. Young<sup>2</sup>, Gerd Bobe<sup>2,5</sup>, Christine M. Perella<sup>4</sup>, Nancy H. Colburn<sup>2</sup>, and George R. Beck, Jr.<sup>1,3</sup>

### Abstract

Recent results suggest a paradigm shift from viewing inorganic phosphate as a passive requirement for basic cell functions to an active regulator of cell behavior. We have previously shown that elevated concentrations of phosphate increased cell proliferation and expression of protumorigenic genes such as Fra-1 and osteopontin in a preosteoblast cell line. Therefore, we hypothesized that elevated phosphate concentrations would promote cell transformation *in vitro* and tumorigenesis *in vivo*. Supplementation of medium with phosphate increased anchorage-independent transformation and proliferation of BALB/c mouse JB6 epidermal cells, activation of N-ras, ERK1/2, and activator protein-1, and increased gene expression of Fra-1, COX-2, and osteopontin in a dose-dependent manner. These *in vitro* results led to the hypothesis that varying the levels of dietary inorganic phosphate would alter tumorigenesis in the mouse model of skin carcinogenesis. Female FVB/N mice were treated with 7,12-dimethylbenz(a)anthracene/12-*O*-tetradecanoylphorbol-13-acetate and fed high- or low-phosphate diets (1.2% versus 0.2% of the diet) for 19 weeks. The high-phosphate diet increased skin papilloma number by ~50% without changing feed intake and body weights. High dietary phosphate increased serum concentrations of phosphate, parathyroid hormone, and osteopontin and decreased serum concentrations of calcium. Thus, we conclude that elevated phosphate promotes cell transformation and skin tumorigenesis partly by increasing the availability of phosphate for activation of N-ras and its downstream targets, which defines reducing dietary phosphate as a novel target for chemoprevention. *Cancer Prev Res*; 3(3); 359–70. ©2010 AACR.

### Introduction

Tumorigenesis is a multistage, complex process often involving both genetic and environmental or lifestyle factors. Lifestyle factors, such as diet, could have a profound influence on the initiation, progression, and/or recovery from disease. This idea is supported by studies evaluating the effects of human migration on the incidence of particular diseases including cancer (reviewed in ref. 1). A general estimate of the potential contribution of diet to cancer ranges from 10% to 70% (2). Diet represents an environmental factor that can be relatively easily manipulated and it is becoming increasingly apparent that diet could

have profound effects on functional genomics (3). However, sufficient information does not currently exist to permit a comprehensive utilization of individual dietary components in the prevention, intervention, and treatment of disease. A number of *in vitro* studies have suggested that inorganic phosphate (Pi) and phosphate transport are necessary for cell growth, essentially acting as a mitogen (4–7); however, little research has been directed at determining the mechanism and the consequences of elevated Pi *in vivo*. Our previous results in a preosteoblast cell line suggested that, *in vitro*, elevated Pi led to increased cell proliferation (8) as well as activation of ERK1/2, changes in protein and gene expression of activator protein-1 (AP-1), and increased expression of transformation-associated proteins such as osteopontin (OPN), Fra-1, and cyclin D1 (8–12). In addition, elevated Pi promotes Akt-ERK1/2-Mnk1 signaling, cap-dependent protein translation, and growth in human lung cells (13). Taken together, the data suggest that the elevated levels of available Pi may be an important driving factor in the growth and transformation potential of cells.

The transformation-sensitive epidermal cell line JB6 is recognized as an excellent model to study multi-stage tumor promotion, including the effects of bioactive food components such as Pi on the process of transformation (14). When treated with various tumor promoters, these cells respond with anchorage-independent growth in soft agar and tumorigenicity (15). Many key factors necessary

**Authors' Affiliations:** <sup>1</sup>Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia; <sup>2</sup>Gene Regulation Section, <sup>3</sup>Laboratory of Cancer Prevention, Center for Cancer Research, <sup>4</sup>Laboratory Animal Sciences Program, Science Applications International Corporation-Frederick, National Cancer Institute, Frederick, Maryland; and <sup>5</sup>Cancer Prevention Fellowship Program, Office of Preventive Oncology, National Cancer Institute, Bethesda, Maryland

**Corresponding Author:** George R. Beck, Jr., Department of Medicine, Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, 101 Woodruff Circle WMRB 1026, Atlanta, GA 30322. Phone: 404-727-1340; Fax: 404-727-1300; E-mail: george.beck@emory.edu.

doi: 10.1158/1940-6207.CAPR-09-0068

©2010 American Association for Cancer Research.

for various steps of the transformation process have been identified and include: activation of members of the AP-1 transcription factor family, an increase in cyclins A, B1, and D1, activation of signaling proteins ERK1/2 and iNOS and increased expression of the extracellular matrix protein osteopontin (reviewed in ref. 16). Members of the AP-1 transcription factor family (17) have also been identified as attractive targets in chemoprevention because their activation is linked to proliferation, transformation, and inflammation (reviewed in ref. 18) in a number of cell types and tissues including skin (19). A number of food factors have been shown to reduce AP-1 activity and thereby reduce the associated transformation properties (reviewed in refs. 18, 20). A gene/protein that is also tightly associated with transformation, inflammation, and metastasis is OPN, an extracellular matrix and circulating factor (21–23). Osteopontin influences cell function by acting as a cytokine through its ability to bind integrin receptors. Recently, OPN was found to be regulated by AP-1 under transforming conditions in the JB6 transformation model (24) and to be strongly regulated by Pi (10). The cellular and molecular events required for transformation in this model have been validated *in vivo* using the 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) two-stage skin carcinogenesis mouse model (23), which is commonly used to study the initiation, promotion, and progression of carcinogenesis (25). The defined molecular mechanisms make the JB6 and two-stage skin carcinogenesis models an excellent system to study the effect of Pi on cell transformation and tumorigenesis.

The ras family (H, K, N, R) of small GTP-binding proteins (~21 kDa) function as important signaling proteins in controlling proliferation, transformation, and tumor invasion (reviewed in ref. 26). Ras proteins are activated in the GTP-bound state and are known to be central to many events related to proliferation, transformation, and tumor invasion through downstream effectors ERK1/2 and Akt. Ras-regulated proliferation and transformation is linked to the regulation of proteins such as cyclin D1, the AP-1 transcription factor Fra-1, and osteopontin, all of which we have previously shown to be responsive to elevated Pi (8, 10, 11). Investigations into the role of ras and tumorigenesis have focused on activating mutations, however, overexpression of ras without activating mutations is also capable of transforming cells (27, 28). Although *in vivo* papilloma formation is known to involve activating mutations in the H-ras isoform and activation of AP-1 transcription (29), the H-ras null mice do form papillomas with 62% having k-ras mutations and 38% having no ras mutations (30).

The objective of the current study was to test the hypothesis that elevated levels of Pi promote proliferation and anchorage-independent growth of transformation-sensitive epidermal cell line JB6 and skin tumorigenesis in DMBA/TPA-treated female FVB/N mice. Furthermore, we explored the molecular mechanism by which Pi alters tumorigenesis and hypothesized that Pi promotes the

activity of ras, ERK1/2, and AP-1, and ultimately, gene expression of Fra-1, COX-2, and osteopontin in a dose-dependent manner.

## Materials and Methods

### Cell culture

Transformation-sensitive JB6 (clone 41) mouse epidermal cells were cultured in monolayers at 37°C and 5% CO<sub>2</sub> using Eagle's minimal essential medium (1 mmol/L Pi; Invitrogen) containing 4% fetal bovine serum (Atlanta Biologicals) supplemented with 2 mmol/L of L-glutamine, 100 units/mL of penicillin and 100 µg/mL of streptomycin (Invitrogen). GDPβS was purchased from Calbiochem. Unless noted, all experiments were done in Eagle's minimal essential medium which contains 1 mmol/L of Pi, and concentrations listed in the figures are final Pi medium concentrations. Added Pi was in the form of NaPO<sub>4</sub> (pH 7.4; Sigma).

### Cell proliferation assays

Cell viability was measured using 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay according to the protocols of the manufacturer (Promega). JB6 cells were plated at  $5 \times 10^3$  cells/100 µL per well in 96-well plates. After 24 h, plated cells were treated with 1 and 2 mmol/L of Pi (1, 2, and 3 mmol/L final) for 36 h. The change in absorbance was measured 1 h after addition of XTT assay reagent on a Bio-Rad Lumimark plate reader (Bio-Rad Laboratories). The results are from six replicates/treatment. Cell counts were done generally as described previously (8). JB6 cells were plated at  $5 \times 10^4$  cells/well of a 12-well plate and cell counts were done after 96 h in medium containing 1 or 3 mmol/L of Pi (final). Cell cycle analysis was done by Flow Cytometry. JB6 cells were subcultured on 10 cm plates and after 48 h, 2 mmol/L of phosphate was added, or not, for a final concentration of 1 and 3 mmol/L. After 36 h, cells were lifted with Accutase (Innovative Cell Technologies, Inc.), washed with PBS, fixed in ethanol, and washed twice. Cells were stained with propidium iodide (Roche) at 0.1 mg/mL final with RNase A (Invitrogen) 1 h prior to analysis by flow cytometry (Accuri Flow Cytometer).

### Anchorage-independent transformation assay

Promotion of neoplastic transformation assays were done as described previously (15). In a 60-mm tissue culture dish, JB6 cells ( $1 \times 10^4$ ) were resuspended in 1.5 mL of 0.33% agar in Eagle's minimal essential medium (1 mmol/L Pi) with 10% fetal bovine serum and layered over 7 mL of 0.5% agar in Eagle's minimal essential medium with 10% fetal bovine serum. Both layers of agar were supplemented with Pi (1.2, 2.2, or 3.7 mmol/L NaPO<sub>4</sub>) in the presence of DMSO or 10 ng/mL phorbol ester TPA (Alexis) in DMSO. The cells were cultured at 36°C for 14 d, stained with neutral red (Sigma) diluted 1:75 in PBS. Colonies

were counted by an automated image analysis system supported by Image Pro-Plus (version 3.0.1) software (Media Cybernetics). Colonies with more than eight cells were scored. The transformation responses are presented as average number of colonies formed per 60 mm tissue culture dish (five replicates/treatment).

### Immunoblotting

JB6 cells were cultured as above and nuclear isolation and immunoblotting were done as described previously (8). Thirty micrograms of lysate were resolved on a 10% SDS-polyacrylamide gel. All antibodies were purchased from (Santa Cruz Biotechnologies, Inc.), except ERK1/2 from (Promega).

### Northern blot assay

Total cell RNA was prepared using Trizol Reagent (Invitrogen) according to the recommendations of the manufacturer. A total of 10 µg of RNA was loaded per lane and separated by electrophoresis through a 1% formaldehyde-agarose gel. The RNA was transferred to a Hybond-N nylon membrane (Amersham Pharmacia Biotech, Inc.), crosslinked by UV irradiation, and baked at 80°C. The <sup>32</sup>P-labeled probes were prepared using a random prime labeling kit (Roche Diagnostics, Corp.). Between successive probes, blots were stripped by treatment with boiling 0.1% SDS. Radiochemicals were obtained from Perkin-Elmer Life Sciences, Inc. The OPN, Fra-1, and actin probes used for Northern blotting have been described previously (8). The cDNA probe for Cox-2 (*ptgs2*) was created by reverse transcription-PCR using primers 5'-ATGCTCTCC-GAGCTGTGCT-3' and 5'-CAGCTCAGTTGAACGCCCTT-3' and Egr1 using primers 5'-ATGGCAGCGGCCCAAGGCC-GAGATGCAATT-3' and 5'-GCAAATTTCAATTGTCCTGGG-3') and cloned into vector TOPO.2.1 (Invitrogen).

### Promoter-luciferase assay

Transformation-sensitive JB6 cells were seeded at  $2 \times 10^4$  per well in a 24-well plate. After 24 h, plated cells were transfected with 4× AP-1 luciferase construct (500 ng/well) and Renilla (50 ng/well; Promega) using Fugene (Roche). After another 24 h, the medium was replaced with DMEM and 0.2% fetal bovine serum (six replicates/treatment). After another 24 h, the medium was supplemented with 1, 2, or 3 mmol/L of Pi for 6 h and DMSO (control) or 10 ng/mL of TPA in DMSO as indicated. The cells were washed in PBS and harvested in 1× lysis buffer. Firefly luciferase and Renilla activities were measured with a luciferase kit from Promega according to the recommendations of the manufacturer on a Turner Biosystems, Inc., microplate luminometer.

### Electrophoretic mobility shift assay

Transformation-sensitive JB6 cells were serum-starved overnight, supplemented with 2 mmol/L of NaPO<sub>4</sub> for 0, 5, 10, 15, 30, and 60 min, and harvested in PBS. To separate nuclear and cytoplasmic fractions, cells were first lysed in a buffer of 0.25 mmol/L HEPES, 50 mmol/L of

KCl, 2 mmol/L of phenylmethylsulfonyl fluoride, 100 µmol/L of DTT, 0.5% NP40, and protease inhibitors (at a final concentration of 2.0 µg/mL aprotinin, 2.0 µg/mL leupeptin, 1.0 µg/mL pepstatin, 100 µmol/L sodium orthovanadate, and 1 mmol/L of DTT). After centrifugation and removal of the cytoplasmic fraction, the nuclear pellet was lysed in an extraction buffer of 0.25 mmol/L of HEPES, 50 mmol/L of KCl, 2 mmol/L of phenylmethylsulfonyl fluoride, 100 µmol/L of DTT, 10% glycerol, and protease inhibitors at the concentrations indicated above. The protein concentration of cell lysates was determined with a BCA Protein Assay Reagent kit (Bio-Rad). Radiolabeled consensus AP-1 oligonucleotides, purchased from Santa Cruz Biotechnology, were generated according to the protocols of the manufacturer (Promega). DNA-binding reactions were done using 5 µg of nuclear extract, 5× Gel Shift Binding Buffer (Promega), labeled oligonucleotide, and nuclease-free water. Reactions were separated on 6% DNA retardation gels (Invitrogen). After separation, the gels were vacuum-dried and exposed to film. The supershift assay was done using nuclear lysate from a sample that was exposed for 5 min with 2 mmol/L of supplemented Pi. Labeled oligonucleotide and nuclear lysate were combined and incubated for 15 min followed by the addition of antibodies of the specific AP-1 family members. All antibodies were purchased from Santa Cruz Biotechnologies.

### Ras activation assay

JB6 cells were serum-starved overnight and supplemented with 0, 2, or 4 mmol/L of NaPO<sub>4</sub> for 5 min (in addition to the 1 mmol/L in the medium). Ras activity was measured using the Ras-binding domain of Raf-1 to pull down active ras according to the protocols of the manufacturer (Cell BioLabs). Blots of whole cell lysate (50 µg) from the input were probed with antibodies to total ERK1/2 (Promega) and phosphorylated ERK1/2 (Santa Cruz Biotechnologies). For time course experiments, JB6 cells were supplemented with 2 mmol/L of Pi for 0, 2.5, 5, 10, or 15 min and ras activation assay was done. To investigate the requirement of phosphate transport, 1 mmol/L of foscarnet (phosphonoformic acid) was added 1 h prior to the supplementation of 2 mmol/L of Pi. Following separation by SDS PAGE, the resulting membrane was probed with a pan-ras antibody followed by N-ras, R-ras, H-ras, and K-ras-specific antibodies (Pan-ras antibody was from Cell BioLabs, all isoform-specific antibodies were purchased from Santa Cruz Biotechnologies).

### Animals and diets

Mice (female FVB/N) were obtained at 4 to 5 wk of age from the National Cancer Institute-Frederick Animal Production Area, Frederick Cancer Research and Development Center (Frederick, MD). Mice were housed in a facility with controlled conditions (temperature, 21-24°C; humidity, 40-70%; light/dark cycle, 12 h light/12 h dark). Until 8 wk of age, mice were fed *ad libitum* NIH-31 diet (1.1% phosphate; Harlan Teklad). At 8 wk of age, mice

were randomly assigned to either a low-phosphate diet (LPD; 0.2% phosphate) or a high-phosphate diet (HPD; 1.2% phosphate; Table 1) both manufactured by TestDiet (Purina Mills). For the two-stage skin carcinogenesis model, 14 mice/group were shaved at 8 wk of age. After 2 d, mice were topically treated with 400 nmol/L of DMBA (Sigma) in 200  $\mu$ L of acetone. Starting 14 d after DMBA initiation, the mice were topically treated with 10 nmol/L of TPA (Alexis) in 200  $\mu$ L of acetone twice a week. Mice were visually examined weekly for skin papilloma and squamous cell carcinoma number and size. Every 3 wk, individual body weights and food disappearance per cage (three or four mice/cage) were measured. Mice were sacrificed at 27 wk of age.

For the serum analysis, five mice/group were fed starting at 8 wk of age the experimental diets for 5 wk. Serum samples were collected from the mice by cardiac puncture. Serum concentrations of phosphorus, calcium, magnesium, creatinine, uric acid, and total protein were measured by the Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD. Serum concentrations of parathyroid hormone (PTH) and insulin growth factor I were measured by AniLytics. In addition, six mice/group were fed starting at 8 wk of age diets containing 0.2% or 1.2% of Pi for 2 wk and then topically treated with 200  $\mu$ L of acetone (control) or TPA (10 nmol/L) in 200  $\mu$ L of acetone. Serum samples were collected by cardiac puncture 6 h after TPA treatment. Serum concentrations of OPN were measured by ELISA (R&D Systems). Animal care and experimental procedures were conducted with the

approval of the National Cancer Institute-Frederick Animal Care and Use Committee.

### Statistical analysis

Statistical analysis was conducted using SAS version 9.1 (SAS, Inc.). For the cell culture studies, a one-way ANOVA was used. When significant effects were detected ( $F$  test significant at  $P < 0.05$ ), we used a two-sided  $t$  test to compare each of the two higher Pi concentrations with the lowest Pi concentration. For the animal studies, papilloma size and mouse weight data were analyzed as a repeated measures study using the mixed models procedure (PROC MIXED). Papilloma size data were transformed to the log ( $X + 0.5$ ) scale so that the data were approximately normally distributed. The fixed effects in the model were dietary Pi (low, high), time (week of age), and the interaction of dietary phosphate and time. A completely unrestricted variance-covariance structure was used to account for repeated measures taken on individual mice across time. The effects of dietary Pi were evaluated by comparing the estimated values at each time point with each other using two-sided  $t$  tests in the LSMEANS statements. Papilloma and squamous cell carcinoma incidence data of the two dietary Pi groups were compared by using Fisher's exact test in PROC FREQ. Concentrations of serum variables of the two dietary Pi groups were compared using a two-sided Student's  $t$  test. Significance was declared at  $P \leq 0.05$  and trends toward significance were declared at  $P \leq 0.10$ . Unadjusted means and SEM are presented.

### Results and Discussion

It is becoming increasingly apparent that diet could have profound effects on functional genomics and represents an area of research that has yet to be exploited for potential health benefits. Pi is a common dietary component that may directly alter cell and tissue behavior in just such a manner. Almost four decades ago, studies noted that contact-inhibited 3T3 cells responded to serum stimulation with a rapid increase in Pi transport (31) and described Pi as a limiting nutrient in proliferation (4–6), capable of actively altering cell growth properties (32) and transformation (7). Recent *in vitro* results suggest that Pi is capable of stimulating specific signal transduction pathways including ERK1/2 and Akt (8, 12, 13), and suggest a paradigm shift from viewing inorganic phosphate as a passive requirement in these processes to an active regulator, thereby defining a novel mitogenic signal. Based on these *in vitro* studies, we hypothesized that Pi is in fact a mitogen. It would then follow that the level of available Pi would actively alter the transformation potential of cells in response to a tumor-promoting event.

#### Elevated phosphate increases proliferation and promotes transformation

We used a number of assays to determine if elevated Pi promotes proliferation. Throughout our *in vitro* studies, we have used a spectrum of final Pi concentrations to cover

**Table 1.** Diet composition

Diet composition	Low phosphate (LPD)	High phosphate (HPD)
Minerals		
Phosphorus (%)	0.17	1.21
Calcium (%)	0.60	0.60
Magnesium (%)	0.07	0.07
Sodium (%)	0.19	0.28
Potassium	0.39	0.39
Nutrients		
Protein (%)	19.00	19.00
Amino acids (%)	Identical	Identical
Fat (%)	10.00	10.00
Cholesterol (ppm)	48.00	48.00
Fiber, max (%)	4.90	4.70
Carbohydrates (%)	60.60	58.10
Energy (kcal/g)	4.09	3.99
Calories provided by		
Protein (%)	18.62	19.09
Fat (%)	22.04	22.59
Carbohydrates (%)	59.34	58.31

NOTE: Full details of diets can be obtained from <http://www.testdiets.com/>.

the physiologic range of both mice and humans. Elevated Pi promoted cell proliferation as measured by cell viability (Fig. 1A), cell number (Fig. 1B), and the percentage of cells in the S and G<sub>2</sub>-M phases of the cell cycle (Fig. 1C). Additionally, elevation of Pi in a physiological range increased the conversion of transformation-sensitive JB6 cells to anchorage-independent growth, which represents a well-defined marker of transformation *in vitro* and correlates specifically with tumorigenicity *in vivo* (33). An increase of as little as 1 mmol/L of Pi alone increased growth and anchorage-independent growth in soft agar (Fig. 1A and D). Supplementation with 1 mmol/L of Pi (in addition to the 1 mmol/L of Pi in the medium) indicates that elevated Pi alone is sufficient to enhance cell transformation. Furthermore, elevated Pi acted synergistically with TPA, which is commonly used to promote cell transformation in JB6 cells, to increase growth in soft agar (Fig. 1D), indicating that Pi renders JB6 cells more sensitive to TPA induced transformation. The soft agar response correlated with a dose-dependent increase in gene expression of OPN, Fra-1, and Cox-2 (Fig. 1E), which are linked to transformation in the JB6 model (22, 27). The augmentation of the TPA response by Pi was also correlated with the expression of osteopontin (Fig. 1F). In particular, OPN (*spp1*) represents a gene/protein that is tightly associated with transformation, inflammation, and metastasis and is an extracellular matrix and circulating factor (21, 22). The growth of JB6 cells in soft agar has been shown to be dependent on OPN expression (34), and recently, OPN was found to be regulated by AP-1 under transforming conditions in JB6 cells model (24). The expression of OPN is often considered a late response, and to determine if elevated Pi resulted in an upstream response, cells were analyzed for gene expression at earlier time points. The results revealed that, in fact, elevated Pi alters the early growth response-1 (*Egr1*) gene within 30 minutes of exposure (Fig. 1G). *Egr1* is considered a marker of cell growth and proliferation and we have previously described it as a Pi-responsive protein (35). Fra-1 and Cox-2 begin to increase later in the response and OPN does not change at these relatively early time points. In summary, our results suggest that high levels of available Pi promote proliferation and transformation as well as the gene expression changes necessary for transformation in JB6 cells.


#### Elevated phosphate activates AP-1

To elucidate the molecular mechanism by which high levels of available Pi promote cell proliferation, transformation, and changes in gene expression, we focused on AP-1 and ras activation. Our previous *in vitro* studies suggested that Pi is a molecule capable of regulating specific signal transduction pathways including ERK1/2 and Akt, and subsequent gene expression leading to increased proliferation (8, 12, 13). The strong link between AP-1 transcription factor activation and JB6 transformation (14, 36–38) and the increased expression of the AP-1 transcription factor Fra-1 in response to Pi (Fig. 1E) suggested that the AP-1 transcription factor family might be responsive to Pi.


Parallel to the soft agar response (Fig. 1D), elevated Pi alone was sufficient to promote AP-1 activity and augment TPA in promoting AP-1 activity (Fig. 2A). The effect of elevated Pi on AP-1 DNA binding was rapid (within 5 minutes; Fig. 2B) and supershifts suggest the presence of at least the AP-1 transcription factors Fra-2, JunB, and FosB at this early time point (Fig. 2C). In agreement with the rapid stimulation of these AP-1 proteins, Fra-2 and JunB have been previously shown to be regulated within 30 to 45 minutes in response to serum stimulation and suggests elevated Pi induces a common, early growth signaling response (39). Although, JunB has also been linked to senescence-promoting activities (40), the strong induction of proliferation by Pi suggests a positive role in this case. It is possible that the dimerization partner may determine the positive or negative effect of JunB on proliferation. To determine if high Pi results in changes in AP-1 protein levels or posttranslational modification(s) nuclear lysate from JB6 cells was analyzed by Western blotting. Results suggest a change in the protein status of Fra-2 with a rapid shift to a slower migrating form in response to elevated Pi (Fig. 2D). Other AP-1 proteins did not seem to be significantly altered at these time points. To confirm changes in gene expression under these conditions, RNA was analyzed for *Egr1* expression and showed a strong increase within 20 minutes of elevated Pi exposure (Fig. 2E). In summary, our results suggest that one potential mechanism by which high levels of available Pi promote cell proliferation and transformation in JB6 cells and the gene expression changes necessary for transformation is by promoting AP-1 DNA binding.

#### Elevated phosphate activates N-ras

Transformation of JB6 cells is dependent on the activation of the Ras-Raf-MEK pathway (41). Our previous studies combining proteomic and microarray analyses in the preosteoblast cell line predicted that the ras family was involved in Pi signaling (10). As hypothesized, elevated Pi promoted within 5 minutes ras activity and ERK1/2 phosphorylation in JB6 cells (Fig. 3A). At this early time point, elevated Pi primarily activated N-ras (Fig. 3B). Reprobing stripped blots with antibodies to H-, K-, and R-ras showed no detectable change in response to Pi (data not shown), suggesting that elevated Pi selectively activates N-ras. Quantification of three experiments suggested a significant time-dependent increase of N-ras activity in response to elevated Pi (Fig. 3C). The Pi-induced increase in N-ras activity at this early time point could be inhibited by blocking phosphate transport into the cell (Fig. 3D), as evaluated by pretreatment with 1 mmol/L of the known phosphate transport inhibitor, phosphonoformic acid, also known as foscarnet (42). This provides strong evidence that the availability of Pi alters N-ras activity and identifies Pi as a novel regulator of ras activity. To determine if GTP signaling occurs upstream of ERK1/2 activation, JB6 cells were serum-starved and pretreated overnight with GDPβS, a stable, inactive analogue of GDP, and treated with phosphate for 10 minutes. The resulting Western blot revealed




**Fig. 1.** High Pi concentrations increase proliferation, anchorage-independent growth, and transformation-responsive gene expression in transformation-sensitive JB6 cells. **A**, high Pi increases proliferation of JB6 cells: cells were plated in a 96-well plate at  $1 \times 10^4/100 \mu\text{L}$  and incubated for 36 h in final medium concentrations of 1, 2, and 3 mmol/L of Pi. Cell growth was measured using XTT assay and results are expressed as the mean XTT reading  $\pm$  SEM (six replicates/treatment). Columns with different characters differ at  $P < 0.001$ . **B**, high Pi increases cell number: JB6 cells were plated at  $5 \times 10^4$  cells/mL and grown in 1 or 3 mmol/L of phosphate (final) for 96 h and cell number recorded. Columns with different characters differ at  $P < 0.05$ . **C**, high Pi increases mitotic cells: JB6 cells were grown in 1 or 3 mmol/L of final Pi for 36 h and analyzed by flow cytometry. Columns with different characters differ at  $P < 0.05$ . **D**, high Pi increases anchorage-independent growth of JB6 cells in soft agar: JB6 cells ( $1 \times 10^4$  cells/ $100 \mu\text{L}$ ) were plated for 14 d in the presence of DMSO (control) or 10 ng/mL of TPA in agar containing 1.2, 2.2, or 3.7 mmol/L of Pi. Colony number, expressed as the mean colony number  $\pm$  SEM (five replicates/treatment), was quantified by staining with neutral red and analyzed by automated microscopy. Columns with different characters differ at  $P < 0.05$ . **E**, high Pi increases transformation-responsive gene expression in JB6 cells: cells were grown for 7 d in medium supplemented with 1.2, 2.2, or 3.7 mmol/L Pi. The RNA was harvested for Northern blotting and probed for osteopontin (OPN), Fra-1, Cox-2, and actin (representative of multiple experiments). **F**, high Pi augments TPA-induced transformation-responsive gene expression: JB6 cells were grown in the presence of 10 ng/mL of TPA in DMSO for 24 h in a medium containing 0.2, 1.2, 2.4, or 4.8 mmol/L of Pi. The resulting RNA samples were analyzed by Northern blotting for OPN, 18S rRNA, and 28S rRNA. **G**, high Pi increases early gene expression: JB6 cells were cultured in growth medium (1 mmol/L Pi) followed by the addition of 4 mmol/L of Pi (5 mmol/L final) for the indicated times. The resulting RNA samples were analyzed by Northern blotting and probed as indicated.



Downloaded from <http://aacrjournals.org/cancerpreventionresearch/article-pdf/3/3/359/2248502/359.pdf> by guest on 20 July 2024

**Fig. 2.** High Pi concentrations increase AP-1 activation in transformation-sensitive JB6 cells. **A**, high Pi increases AP-1 transcriptional activity in JB6 cells: cells were transfected with a 4x AP-1 luciferase and Renilla reporter constructs, and after 24 h serum-starved overnight. Medium was then supplemented to a final concentration of 1, 2, or 3 mmol/L of Pi in the presence of DMSO (control) or 10 ng/mL of TPA in DMSO for 6 h. AP-1 transcriptional activity was measured using a luciferase reporter assay (six replicates/treatment) and Renilla by Stop-and-Glo. Luciferase activity was then normalized to Renilla and averaged. Columns with different characters differ at  $P < 0.05$ . **B**, high Pi increases within 5 min AP-1 DNA binding in JB6 cells: cells were supplemented with 2 mmol/L of Pi for 0, 5, 10, 15, 30, or 60 min and EMSA was done using an oligo containing a consensus AP-1 binding element. **C**, high Pi primarily increases within 5 min DNA binding of the AP-1 proteins Fra-2, JunB, and FosB: cells were supplemented with 2 mmol/L of Pi for 5 min and EMSA was done using an oligo containing a consensus AP-1 element and antibodies specific to the seven individual AP-1 family members (Fra-1, Fra-2, c-fos, FosB, JunB, c-Jun, and JunD) and CREB (representative of multiple experiments). **D**, high Pi alters AP-1 protein forms: JB6 cells were serum-starved (1 mmol/L Pi) followed by the addition of 2 mmol/L of Pi (3 mmol/L final) for the indicated times. Nuclear lysates were analyzed by Western blotting and probed as indicated. **E**, high Pi increases Egr1 expression within 20 min. JB6 cells were treated as in **D** and cells harvested for Northern analysis. Results are representative of multiple experiments.



**Fig. 3.** High Pi concentrations activate N-ras in transformation-sensitive JB6 cells. **A**, high Pi increases within 5 min ras activity and phosphorylation of ERK1/2 in JB6 cells: cells were serum-starved overnight and supplemented with 2 or 4 mmol/L of Pi for 5 min (1, 3, and 5 mmol/L final). Ras activation of whole cell lysate blots was measured using the Ras-binding domain of Raf-1 and detected using pan-ras antibody. Phosphorylation of ERK1/2 was measured from a duplicate whole cell lysate blot using phosphorylated ERK1/2 antibody. **B**, high Pi increases within 2.5 min N-ras activity and phosphorylation of ERK1/2 in JB6 cells: cells were serum-starved overnight and treated with 2 mmol/L of Pi (3 mmol/L final) for 0, 2.5, 5, 10, and 15 min. A ras activation assay was done (active ras) and whole cell lysate (WCL) from the same samples were probed with antibodies for N-ras and phosphorylated ERK1/2, respectively. **C**, quantitation of N-ras activity at 0, 2.5, and 5 min from three separate experiments: results are expressed as arbitrary units obtained from densitometry analysis. Columns with different characters differ at  $P < 0.05$ . **D**, phosphate transport is required for Pi to increase N-ras activity: cells were serum starved overnight and supplemented for 2.5 min with 0 or 2 mmol/L of Pi and vehicle ( $H_2O$ ) or 1 mmol/L of the phosphate transport inhibitor foscarnet [phosphonoformic acid (FOS)]. Ras activation (active ras) and whole cell lysate (WCL) blots were probed with antibodies for N-ras. **E**, inhibition of GDP/GTP exchange blocks Pi induced ERK1/2 phosphorylation: JB6 cells were serum-starved overnight (1 mmol/L Pi) and pretreated with 2.5 mmol/L of GDPβS. The cells were treated with 2 mmol/L of Pi (3 mmol/L final) for 10 min and resulting cell lysates analyzed by Western blotting.

that inhibition of GTP signaling blocked phosphorylation of ERK1/2, suggesting the GTP signaling event is upstream (Fig. 3E).

The *N-ras* knockout mice are viable and grow normally (43); however, these mice are less responsive to carcinogen-induced tumors than wild-type mice and overexpression of wild-type *N-ras* has been shown to increase the incidence of lymphomas (44). To our knowledge, the *N-ras* null mouse has not been tested in the two-stage model. Our data suggest that normally activated *N-ras* cooperates with activated *H-ras* to enhance tumor formation, progression, or both. A precedent for such a scenario has been suggested using the *N-ras* null mice. This study showed the stimulation of Raf and Rhoa by *N-ras* and Akt and simultaneous activation of *cdc42* by *K-ras* to cooperate in

transformation (45). Another study using a colon cancer model showed that expression of active *K-Ras* (G12D) altered proliferation whereas active *N-Ras* (G12D) altered apoptosis, again suggesting unique, nonoverlapping, and cooperative roles for the ras isoforms in transformation (46). In summary, our results suggest that another potential mechanism by which high levels of available Pi promote cell proliferation, transformation, and gene expression in JB6 cells is by activating a Ras signaling network.

#### HPD increases sensitivity to skin papillomagenesis

The JB6 transformation model has been shown to be predictive of results in the two-stage skin carcinogenesis model. Consistent with the results in the JB6 model, high dietary phosphate (HPD, 1.2% Pi) increased skin




papilloma number by 50% compared with low dietary phosphate (LPD, 0.2% Pi) in DMBA/TPA-treated female *FVB/N* mice (Fig. 4A and B). Similarly, in a recent study of lung tumorigenesis in mice, high dietary Pi (1.0%) increased tumor number and size compared with 0.5% Pi (47), suggesting a general promoting effect of high dietary phosphate level on tumorigenesis. Although all mice developed at least one papilloma and papillomas of similar size at the end of trial, there was a trend toward delayed incidence and growth (Fig. 4B and C). Speculatively, mice on the HPD develop papillomas earlier and more papillomas might progress to squamous cell carcinoma than the mice on the LPD (HPD, 3.9% or 5 of 127 papillomas versus LPD; 2.3% or 2 of 86 papillomas), although more data are needed for statistical validation of these observations. However, the fact that the papillomas were smaller in size with the LPD and taken with a recent study which showed that HPD stimulated increased cell proliferation and lung tumorigenesis of K-ras active mice (47) suggests that the HPD does accelerate proliferation. Neither of the Pi diets affected body weight (Fig. 4D) or feed consumption (data

not shown), which is consistent with the results in the lung tumorigenesis model (47). In summary, our results suggest that high dietary Pi promotes skin tumorigenesis in DMBA/TPA-treated female *FVB/N* mice.

#### HPD increases serum osteopontin levels

Altered serum phosphate might not only influence cell and tissue behavior by cell autonomous effects but also paracrine and endocrine effects. Levels of serum phosphate in mice and humans have been shown to be positively correlated to PTH levels (48, 49). Although the receptor for PTH has been identified in rodent keratinocytes (50), the presence in human keratinocytes is not clear (51), and little is known about its potential effects on cell behavior. We found that HPD increased serum concentrations of phosphate and PTH, and decreased concentrations of calcium and uric acid, whereas serum insulin growth factor-I, magnesium, creatinine, and total protein concentrations were not affected (Table 2; Fig. 5A). This suggests a specific rather than a general effect of dietary Pi on circulating factors. Here, we report an



**Fig. 4.** HPD promotes skin tumorigenesis in DMBA/TPA-treated *FVB/N* mice. **A**, HPD increases skin papilloma number in DMBA/TPA-treated *FVB/N* mice: skin papilloma numbers were counted weekly from 14 mice/group that were fed for 19 wk with HPD (1.2% Pi) or LPD (0.2% Pi) starting with the DMBA initiation. \*, differences between dietary groups at  $P < 0.05$ . **B**, HPD accelerates early skin papilloma growth: skin papilloma dimensions were measured weekly from 14 mice/group that were fed for 19 wk with HPD or LPD starting with the DMBA initiation. \*, differences between dietary groups at  $P < 0.05$ . **C**, HPD accelerates the first appearance of skin papilloma number in DMBA/TPA-treated *FVB/N* mice: skin papilloma numbers were counted weekly from 14 mice/group that were fed for 19 wk with HPD (1.2% Pi) or LPDs (0.2% Pi) starting with the DMBA initiation. \*, differences between dietary groups at  $P \leq 0.05$ . **D**, the LPD does not affect body weight in DMBA/TPA-treated *FVB/N* mice: individual body weight was measured every 3 wk from 14 mice/group that were fed for 19 wk with HPD or LPD starting with the DMBA initiation.

**Table 2.** High Pi consumption (in % of diet) increases serum concentrations of phosphate and decreases concentrations of calcium and uric acid in *FVB/N* mice ( $n = 5/\text{group}$ )

Diet	Phosphorus (mg/dL)	Calcium (mg/dL)	Magnesium (mg/dL)	Creatinine (mg/dL)	Uric acid (mg/dL)	Total protein (g/dL)
0.2% Pi	6.71 ± 0.60	10.38 ± 0.36	2.44 ± 0.17	0.14 ± 0.02	1.84 ± 0.11	5.70 ± 0.27
1.2% Pi	10.60 ± 1.81*	9.77 ± 0.24†	2.59 ± 0.13	0.18 ± 0.03	1.38 ± 0.28†	5.84 ± 0.37


\* $P \leq 0.001$ .† $P \leq 0.01$ .

additional circulating serum factor that is Pi-responsive, OPN (Fig. 5B). Osteopontin is known as both a survival factor and as a mediator of macrophage infiltration to the tumor site (52). Therefore, elevated circulating OPN concentrations might promote tumor initiation and progression. Consistent with our results in JB6 cells (Fig. 1), high dietary Pi increased synergistically with TPA serum concentrations of OPN (Fig. 5B). In summary, our results suggest that an additional mechanism by which changes in serum Pi might promote tumorigenesis is by increasing the levels of circulating OPN.

#### Dietary phosphate can effect steady state serum phosphate levels

Our *in vitro* studies were done using a spectrum of Pi concentrations physiologically relevant to both humans and mice. In humans, steady-state serum phosphate con-

centrations generally range from 0.70 to 1.55 mmol/L, although levels differ slightly with sex and age. However, serum levels in humans could vary by as much as 1.2 mmol/L following a high-phosphate meal and remain stably altered from diet alone (53–55). Although basal serum phosphate levels are different between mice and humans, the percentage of change we achieved in our study is in line with what is achievable in humans. The diets used herein resulted in a change in serum phosphate from 2.17 mmol/L (LPD) to 3.42 mmol/L (HPD), a 37% difference (Table 2). The change is proportional to differences found in humans in response to altered Pi diets (53, 54, 56). The results presented here suggest that differences in dietary Pi could cause significant long-term differences in steady-state serum phosphate levels in agreement with other published long-term diet studies in both rodents (57, 58) and humans (48, 53, 56, 59, 60). Due in part



**Fig. 5.** A HPD increases serum concentrations of PTH in *FVB/N* mice and osteopontin (OPN) in TPA-treated *FVB/N* mice. A, a HPD increases serum concentrations of PTH, but not insulin growth factor-I in *FVB/N* mice: serum samples were taken from five mice per group that were fed for 5 wk with HPD (1.2% Pi) or LPDs (0.2% Pi), and analyzed for PTH and insulin growth factor-I. Columns with different characters differ at  $P < 0.05$ . B, a HPD increases the serum concentrations of OPN in TPA-treated *FVB/N* mice: serum samples were taken from six mice per group that were fed for 2 wk with HPD (1.2% Pi) or LPD (0.2% Pi), and then were treated topically 6 h before sample collection with acetone (control) or 10 nmol/L of TPA in acetone. Columns with different characters differ at  $P < 0.01$ .

to the increased consumption of processed foods, the amount of Pi in the American diet continues to increase above levels already considered high by the Food and Drug Administration (59). The current dietary recommended allowance for Pi is 700 to 800 mg/d, and the tolerable upper intake limit is 4,000 mg/d for adults. It is important to note that the diets reported here have increased Pi without corresponding changes in calcium as would be the case with a diet high in dairy (59). A human dietary equivalent of the daily Pi consumption of our mice is 500 mg/d for the LPD and 1,800 mg/d for the HPD. More than 50% of young and middle aged men consume >1,600 mg/d and these calculations largely reflect "natural" sources of Pi and are therefore likely an underestimate (61).

In conclusion, the *in vitro* and *in vivo* results reveal that elevated Pi promotes cell transformation and skin tumorigenesis and suggest at least two different means. First, elevated Pi may act in a cell autonomous manner as a mitogen and promote proliferation and transformation through activation of a signaling pathway consisting of ras and ERK1/2. Elevated Pi may promote AP-1 transcriptional activation early in the response and ultimately changes in gene expression such as OPN, a known autocrine, paracrine, and endocrine factor later in the response. Secondly, elevated Pi increases circulating concentrations of PTH and OPN, both of which could act as endocrine

factors and promote tumorigenesis. The significance of OPN in papilloma formation in the two-stage model has been recently shown using the OPN-null mice in which the lack of osteopontin markedly suppressed papilloma development, possibly through the prevention of apoptosis (62). As the amount of Pi in the human diet, and in particular the western diet, continues to increase (59), it will be important to fully understand the influence of Pi on cell and tissue function and the relationship to tumorigenesis (63). Furthermore, these studies identify dietary Pi as a novel target for chemoprevention.

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

### Grant Support

G.R. Beck, Jr. and C.E. Camalier are supported in part by grants from the NIH/National Cancer Institute (CA136059), NIH/NIAMS (AR056090), Emory University Research Committee grant, and M.R. Young, G. Bobe, C.M. Perella, and N.H. Colburn supported by federal funds from the National Cancer Institute, NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 04/06/2009; revised 11/05/2009; accepted 11/06/2009; published OnlineFirst 02/09/2010.

### References

- Newberne PM, Conner MW. Dietary modifiers of cancer. *Prog Clin Biol Res* 1988;259:105–29.
- Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. *J Natl Cancer Inst* 1981;66:1191–308.
- Go VL, Wong DA, Wang Y, Butrum RR, Norman HA, Wilkerson L. Diet and cancer prevention: evidence-based medicine to genomic medicine. *J Nutr* 2004;134:3513–6S.
- Holley RW, Kieman JA. Control of the initiation of DNA synthesis in 3T3 cells: low-molecular weight nutrients. *Proc Natl Acad Sci U S A* 1974;71:2942–5.
- Weber MJ, Edlin G. Phosphate transport, nucleotide pools, and ribonucleic acid synthesis in growing and in density-inhibited 3T3 cells. *J Biol Chem* 1971;246:1828–33.
- Hilborn DA. Serum stimulation of phosphate uptake into 3T3 cells. *J Cell Physiol* 1976;87:111–21.
- Rubin H, Sanui H. Complexes of inorganic pyrophosphate, orthophosphate, and calcium as stimulants of 3T3 cell multiplication. *Proc Natl Acad Sci U S A* 1977;74:5026–30.
- Conrads KA, Yi M, Simpson KA, et al. A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. *Mol Cell Proteomics* 2005;4:1284–96.
- Beck GR, Jr., Moran E, Knecht N. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. *Exp Cell Res* 2003;288:288–300.
- Beck GR, Jr., Zerler B, Moran E. Phosphate is a specific signal for induction of osteopontin gene expression. *Proc Natl Acad Sci U S A* 2000;97:8352–7.
- Conrads KA, Yu LR, Lucas DA, et al. Quantitative proteomic analysis of inorganic phosphate-induced murine MC3T3-1 osteoblast cells. *Electrophoresis* 2004;25:1342–52.
- Beck GR, Jr., Knecht N. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. *J Biol Chem* 2003;278:41921–9.
- Chang SH, Yu KN, Lee YS, et al. Elevated inorganic phosphate stimulates Akt-ERK1/2-Mnk1 signaling in human lung cells. *Am J Respir Cell Mol Biol* 2006;35:528–39.
- Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. *Science* 1989;244:566–9.
- Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. *Nature* 1979;281:589–91.
- Dhar A, Hu J, Reeves R, Resar LM, Colburn NH. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. *Oncogene* 2004;23:4466–76.
- Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta* 1991;1072:129–57.
- Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol* 2006;71:1397–421.
- Gupta S, Mukhtar H. Chemoprevention of skin cancer: current status and future prospects. *Cancer Metastasis Rev* 2002;21:363–80.
- Dong Z. Effects of food factors on signal transduction pathways. *Biofactors* 2000;12:17–28.
- Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. *Clin Exp Metastasis* 2003;20:77–84.
- Rittling SR, Chambers AF. Role of osteopontin in tumour progression. *Br J Cancer* 2004;90:1877–81.

23. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. *Cytokine Growth Factor Rev* 2006;17:463–74.
24. Matthews CP, Birkholz AM, Baker AR, et al. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. *Cancer Res* 2007;67:2430–8.
25. Slaga TJ, Budunova IV, Gimenez-Conti IB, Aldaz CM. The mouse skin carcinogenesis model. *J Invest Dermatol Symp Proc* 1996;1:151–6.
26. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. *Front Biosci* 1998;3:d887–912.
27. Barbacid M. ras genes. *Annu Rev Biochem* 1987;56:779–827.
28. Mangues R, Seidman I, Gordon JW, Pellicer A. Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. *Oncogene* 1992;7:2073–6.
29. Wasylyk C, Imler JL, Wasylyk B. Transforming but not immortalizing oncogenes activate the transcription factor PEA1. *EMBO J* 1988;7:2475–83.
30. Ise K, Nakamura K, Nakao K, et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. *Oncogene* 2000;19:2951–6.
31. Cunningham DD, Pardee AB. Transport changes rapidly initiated by serum addition to "contact inhibited" 3T3 cells. *Proc Natl Acad Sci U S A* 1969;64:1049–56.
32. Engstrom W, Zetterberg A. Phosphate and the regulation of DNA replication in normal and virus-transformed 3T3 cells. *Biochem J* 1983;214:695–702.
33. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth *in vitro*. *Proc Natl Acad Sci U S A* 1975;72:4435–9.
34. Chang PL, Cao M, Hicks P. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. *Carcinogenesis* 2003;24:1749–58.
35. Meng Z, Camalier CE, Lucas DA, Veenstra TD, Beck GR, Jr., Conrads TP. Probing early growth response 1 interacting proteins at the active promoter in osteoblast cells using oligoprecipitation and mass spectrometry. *J Proteome Res* 2006;5:1931–9.
36. Bernstein LR, Bravo R, Colburn NH. 12-O-tetradecanoylphorbol-13-acetate-induced levels of AP-1 proteins: a 46-kDa protein immunoprecipitated by anti-fra-1 and induced in promotion-resistant but not promotion-sensitive JB6 cells. *Mol Carcinog* 1992;6:221–9.
37. Dong Z, Lavrovsky V, Colburn NH. Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. *Carcinogenesis* 1995;16:749–56.
38. Young MR, Nair R, Bucheimer N, et al. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. *Mol Cell Biol* 2002;22:587–98.
39. Kovary K, Bravo R. Existence of different Fos/Jun complexes during the G0-to-G1 transition and during exponential growth in mouse fibroblasts: differential role of Fos proteins. *Mol Cell Biol* 1992;12:5015–23.
40. Piechaczyk M, Farras R. Regulation and function of JunB in cell proliferation. *Biochem Soc Trans* 2008;36:864–7.
41. Kang NJ, Lee KW, Kwon JY, et al. Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase signaling. *Cancer Prev Res* 2008;1:522–31.
42. Szczepanska-Konkel M, Yusufi AN, VanScoy M, Webster SK, Dousa TP. Phosphonocarboxylic acids as specific inhibitors of Na<sup>+</sup>-dependent transport of phosphate across renal brush border membrane. *J Biol Chem* 1986;261:6375–83.
43. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R. The murine N-ras gene is not essential for growth and development. *Proc Natl Acad Sci U S A* 1995;92:1709–13.
44. Diaz R, Lopez-Barcons L, Ahn D, et al. Complex effects of Ras proto-oncogenes in tumorigenesis. *Carcinogenesis* 2004;25:535–9.
45. Fotiadou PP, Takahashi C, Rajabi HN, Ewen ME. Wild-type NRas and KRas perform distinct functions during transformation. *Mol Cell Biol* 2007;27:6742–55.
46. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. *Nat Genet* 2008;40:600–8.
47. Jin H, Xu CX, Lim HT, et al. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. *Am J Respir Crit Care Med* 2009;179:59–68.
48. Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL. The role of phosphate in the secretion of parathyroid hormone in man. *J Clin Invest* 1970;49:2146–9.
49. Calvo MS, Kumar R, Heath H. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets. *J Clin Endocrinol Metab* 1990;70:1334–40.
50. Errazahi A, Bouizar Z, Lieberherr M, Souil E, Rizk-Rabin M. Functional type I PTH/PTHrP receptor in freshly isolated newborn rat keratinocytes: identification by RT-PCR and immunohistochemistry. *J Bone Miner Res* 2003;18:737–50.
51. Sharpe GR, Dillon JP, Durham B, Gallagher JA, Fraser WD. Human keratinocytes express transcripts for three isoforms of parathyroid hormone-related protein (PTHrP), but not for the parathyroid hormone/PTHrP receptor: effects of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub>. *Br J Dermatol* 1998;138:944–51.
52. Duff MD, Mestre J, Maddali S, Yan ZP, Stapleton P, Daly JM. Analysis of gene expression in the tumor-associated macrophage. *J Surg Res* 2007;142:119–28.
53. Portale AA, Halloran BP, Murphy MM, Morris RC, Jr. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. *J Clin Invest* 1986;77:7–12.
54. Portale AA, Halloran BP, Morris RC, Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. *J Clin Invest* 1989;83:1494–9.
55. Kemi VE, Karkkainen MU, Lamberg-Allardt CJ. High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-dependent manner in healthy young females. *Br J Nutr* 2006;96:545–52.
56. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. *Kidney Int* 2006;70:2141–7.
57. Katsumata S, Masuyama R, Koshihara M, Matsuzaki H, Uehara M, Suzuki K. High phosphorus diet changes phosphorus metabolism regardless of PTH action in rats. *Biosci Biotechnol Biochem* 2004;68:243–6.
58. Czarnogorski M, Woda CB, Schulkin J, Mulroney SE. Induction of a phosphate appetite in adult male and female rats. *Exp Biol Med (Maywood)* 2004;229:914–9.
59. Calvo MS. Dietary phosphorus, calcium metabolism and bone. *J Nutr* 1993;123:1627–33.
60. Huttunen MM, Tillman I, Viljakainen HT, et al. High dietary phosphate intake reduces bone strength in the growing rat skeleton. *J Bone Miner Res* 2007;22:83–92.
61. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? *Semin Dial* 2003;16:186–8.
62. Hsieh YH, Juliana MM, Hicks PH, et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. *Cancer Res* 2006;66:7119–27.
63. McCarty MF. A moderately low phosphate intake may provide health benefits analogous to those conferred by UV light—a further advantage of vegan diets. *Med Hypotheses* 2003;61:543–60.